19
Jan 21
Theranexus implements a new equity line of an amount of up to €8.4 million in total over 12 months
Lyon, 18 January 2021 – Theranexus, a biopharmaceutical company innovating in the treatment of neurologicaldiseases and pioneer in the development of drug candidates modulating the interaction between neurons and glialcells, presents an update on its activities and announces the strengthening of its financial visibilityfor the medium term.